Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

Publisher： Karger

E-ISSN： 1421-9913|44|1|22-30

ISSN： 0014-3022

Source： European Neurology, Vol.44, Iss.1, 2000-07, pp. : 22-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease?

By  

European Neurology, Vol. 63, Iss. 5, 2010-03 ,pp. : 257-266

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

By  

European Neurology, Vol. 45, Iss. 2, 2001-02 ,pp. : 111-118

Karger

Access to resources Recommend Favorite

Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment

By  

European Neurology, Vol. 53, Iss. 4, 2005-07 ,pp. : 197-202

Karger

Access to resources Recommend Favorite

Pharmacokinetic Studies with a Dual-Release Formulation of Levodopa, a Novel Principle in the Treatment of Parkinson’s Disease

By  

European Neurology, Vol. 39, Iss. 2, 1998-02 ,pp. : 119-124

Karger

Access to resources Recommend Favorite

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

By  

European Neurology, Vol. 60, Iss. 2, 2008-05 ,pp. : 57-66

Karger

Access to resources Recommend Favorite